☰

Darren R. Veach, Ph.D. - Publications

Affiliations: 
2001 University of Cincinnati, Cincinnati, OH 
Area:
Organic Chemistry, Biochemistry, Molecular Biology
Tree Info Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, Larson SM. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 73S-78S. PMID 27694177 DOI: 10.2967/jnumed.115.170134  0.76
2016 Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. Ejnmmi Research. 6: 7. PMID 26801327 DOI: 10.1186/s13550-016-0164-0  0.76
2014 Kim TS, Cavnar MJ, Cohen NA, Sorenson EC, Greer JB, Seifert AM, Crawley MH, Green BL, Popow R, Pillarsetty N, Veach DR, Ku AT, Rossi F, Besmer P, Antonescu CR, et al. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2350-62. PMID 24583793 DOI: 10.1158/1078-0432.CCR-13-3033  0.76
2012 Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, Zanzonico PB, Longo V, Holland EC, Larson SM, Bradbury MS. Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia (New York, N.Y.). 14: 1132-43. PMID 23308046 DOI: 10.1593/neo.121750  0.76
2012 Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, de Stanchina E, Veach DR, Scandura JM, Manova-Todorova K, Moore MA, Antonescu CR, Besmer P. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America. 109: E2276-83. PMID 22652566 DOI: 10.1073/pnas.1115240109  0.76
2012 Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S. Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 25-31. PMID 21161687 DOI: 10.1007/s11307-010-0462-2  0.76
2011 Zhou G, Sylvester JE, Wu D, Veach DR, Kron SJ. A magnetic bead-based protein kinase assay with dual detection techniques. Analytical Biochemistry. 408: 5-11. PMID 20807497 DOI: 10.1016/j.ab.2010.08.034  0.76
2010 Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, Giancotti FG, Antonescu CR, Besmer P. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Molecular Cancer Research : McR. 8: 1271-83. PMID 20736294 DOI: 10.1158/1541-7786.MCR-10-0065  0.76
2010 Mand MR, Wu D, Veach DR, Kron SJ. Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. Journal of Biomolecular Screening. 15: 434-40. PMID 20237206 DOI: 10.1177/1087057110363307  0.76
2010 Doubrovin M, Kochetkova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, Balatoni J, Bornmann W, Gelovani J, Larson SM. (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 121-9. PMID 20048131 DOI: 10.2967/jnumed.109.066126  0.76
2009 Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H. Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 6872-6. PMID 19889540 DOI: 10.1016/j.bmcl.2009.10.085  0.76
2008 Wu D, Mand MR, Veach DR, Parker LL, Clarkson B, Kron SJ. A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. Analytical Biochemistry. 375: 18-26. PMID 18194660 DOI: 10.1016/j.ab.2007.12.023  0.76
2007 Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. The Journal of Clinical Investigation. 117: 3846-56. PMID 18060032 DOI: 10.1172/JCI31871  0.76
2007 Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. Journal of Medicinal Chemistry. 50: 5853-7. PMID 17956080 DOI: 10.1021/jm070342g  0.76
2006 Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh MD, Pope RM. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics. 6: 4554-64. PMID 16858728 DOI: 10.1002/pmic.200600109  0.76
2006 Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 103: 9244-9. PMID 16754879 DOI: 10.1073/pnas.0600001103  0.76
2006 Wendel HG, De Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition Proceedings of the National Academy of Sciences of the United States of America. 103: 7444-7449. PMID 16651519 DOI: 10.1073/pnas.0602402103  0.76
2005 Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Medicine. 11: 731-9. PMID 15980865 DOI: 10.1038/nm1265  0.76
2005 Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM. Synthesis and in vitro examination of [124I]-, [ 125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors Nuclear Medicine and Biology. 32: 313-321. PMID 15878500 DOI: 10.1016/j.nucmedbio.2005.01.008  0.76
2005 Mack ET, Birzniece D, Veach DR, Coyle W, Wilson RM. DNA photocleavage and biological activity of a pyrene dihydrodioxin. Bioorganic & Medicinal Chemistry Letters. 15: 2173-6. PMID 15808491 DOI: 10.1016/j.bmcl.2005.02.003  0.76
2005 Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia Blood. 105: 3995-4003. PMID 15657179 DOI: 10.1182/blood-2004-09-3534  0.76
2005 von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood. 105: 1652-9. PMID 15459011 DOI: 10.1182/blood-2004-06-2445  0.76
2004 Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate Leukemia. 18: 1352-1356. PMID 15201856 DOI: 10.1038/sj.leu.2403416  0.76
2004 Swimm A, Bommarius B, Li Y, Cheng D, Reeves P, Sherman M, Veach D, Bornmann W, Kalman D. Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Molecular Biology of the Cell. 15: 3520-9. PMID 15155808 DOI: 10.1091/mbc.E04-02-0093  0.76
2003 von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Research. 63: 6395-404. PMID 14559829  0.76
2003 Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proceedings of the National Academy of Sciences of the United States of America. 100: 12444-9. PMID 14523244 DOI: 10.1073/pnas.1534745100  0.76
2003 Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Molecular and Cellular Biology. 23: 3884-96. PMID 12748290 DOI: 10.1128/MCB.23.11.3884-3896.2003  0.76
2003 Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell. 112: 859-871. PMID 12654251 DOI: 10.1016/S0092-8674(03)00194-6  0.76
2002 Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases Cancer Research. 62: 4244-4255. PMID 12154026  0.76
2002 Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research. 62: 4236-43. PMID 12154025  0.76
2001 Hofmann RM, Cotton GJ, Chang EJ, Vidal E, Veach D, Bornmann W, Muir TW. Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity. Bioorganic & Medicinal Chemistry Letters. 11: 3091-4. PMID 11720849 DOI: 10.1016/S0960-894X(01)00650-3  0.76
Show low-probability matches.